|
|
|
|
| LEADER |
01604nam a2200253 u 4500 |
| 001 |
EB002191831 |
| 003 |
EBX01000000000000001329296 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
240105 r ||| eng |
| 100 |
1 |
|
|a Tran, Khai
|
| 245 |
0 |
0 |
|a Lurasidone hydrochloride for bipolar disorder
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Khai Tran, Caitlyn Ford
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c February 20, 2020, 2020
|
| 300 |
|
|
|a 1 PDF file (32 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Ford, Caitlyn
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK562948
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The aim of this report is to review the comparative clinical effectiveness and cost-effectiveness of lurasidone hydrochloride (as monotherapy or as adjunctive therapy with lithium or valproate) versus other treatments such as typical antipsychotics, other atypical antipsychotics, lithium, lamotrigine, antidepressants, valproate, or tryptophan, for the treatment of adults with BD. This report also aims to identify safety-related outcomes and evidence-based guidelines regarding the use of lurasidone hydrochloride for the treatment of adults with BD.
|